J V Torregrosa
Overview
Explore the profile of J V Torregrosa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perello J, Gomez M, Ferrer M, Rodriguez N, Salcedo C, Buades J, et al.
J Nephrol
. 2018 Jan;
31(2):287-296.
PMID: 29350348
Background: Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor...
2.
Florit E, Bennis S, Rodriguez E, Revuelta I, de Sousa E, Esforzado N, et al.
Transplant Proc
. 2015 Nov;
47(8):2351-3.
PMID: 26518924
Introduction: The aim of this study was to compare the group of patients receiving a new kidney transplant before starting dialysis again (pre-reTR) with a group of patients receiving a...
3.
Gelpi R, Cid J, Lozano M, Revuelta I, Sanchez-Escuredo A, Blasco M, et al.
Transplant Proc
. 2015 Nov;
47(8):2340-3.
PMID: 26518921
Background: In ABO-incompatible (ABOi) kidney transplantation (KT) with low iso-agglutinin (IG) titers (IGT), standard pre-conditioning treatment might be excessive. To try to answer this question, we evaluated the pre-conditioning requirements...
4.
Sanchez-Escuredo A, Alsina A, Diekmann F, Revuelta I, Esforzado N, Ricart M, et al.
Transplant Proc
. 2015 Feb;
47(1):30-3.
PMID: 25645763
Introduction: End-stage renal disease (ESRD) is a major public health problem in the Spanish health system. Kidney transplantation is the treatment of choice, offering better survival and cost-effectiveness than other...
5.
Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, et al.
Am J Transplant
. 2014 Sep;
14(11):2545-55.
PMID: 25225081
Persistent hyperparathyroidism (HPT) after kidney transplantation (KTx) is associated with hypercalcemia, hypophosphatemia and abnormally high levels of parathyroid hormone (PTH). In this randomized trial, cinacalcet was compared to placebo for...
6.
Paschoalin R, Torregrosa J, Barros X, Duran C, Soler M, Campistol J
Transplant Proc
. 2012 Oct;
44(8):2379-80.
PMID: 23026598
Background: Secondary hyperparathyroidism is a relevant problem in patients on dialysis. Cinacalcet in regular clinical practice increases the percentage of patients achieving treatment targets for PTH, Ca and P. We...
7.
Paschoalin R, Torregrosa J, Barros X, Duran C, Campistol J
Transplant Proc
. 2012 Oct;
44(8):2376-8.
PMID: 23026597
Background: Secondary hyperparathyroidism that persists after kidney transplantation (KT), is the main cause of hypercalcemia. Cinacalcet has been used to control hypercalcemia in KT patients. Objective: The aim of this...
8.
Duran C, Torregrosa J, Canalejo A, Almaden Y, Campistol J, Rodriguez Portillo M
Nefrologia
. 2010 Jul;
30(4):413-9.
PMID: 20651882
Aim: To compare the dynamics of calcium-regulated PTH secretion in vitro from adenomatous versus hyperplastic glands and to investigate the relationship between the parathyroid cell cycle and the calcium-regulated PTH...
9.
Torregrosa J, Ramos A
Nefrologia
. 2010 Jun;
30(3):288-96.
PMID: 20514097
Bisphosphonates are synthetic compounds similar to organic pyrophosphates. The bioavailability of intravenous preparations is 100%, whereas the availability of oral therapy ranges from 1 to 5%. About 50% to 80%...
10.
Baccaro M, Pepin M, Guevara M, Colmenero J, Torregrosa J, Martin-Llahi M, et al.
Nephrol Dial Transplant
. 2010 Feb;
25(7):2356-63.
PMID: 20139064
The outcome of patients with cirrhosis and chronic kidney disease treated with combined liver-kidney transplantation (CLKT) is not well known because most series of patients treated with CLKT include not...